PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis

Table 2 Characteristics of patients who underwent allo-HSCT

Patient no.	Disease status	HSCT method	Donor	Conditioning regimen	GVHD prophylaxis	Adverse reactions	Outcome	Causes of death
1	CR	HLA 5/10 related donor	Sister	TBI/Cy/VP-16	CsA + MTX + ATG	Recurrence, acute GVHD I, sepsis	Died	Recurrence, sepsis
2	PR	HLA5/10 related donor	Brother	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD III	Survival	–
3	CR	HLA10/10 related donor	Sister	TBI/Cy/VP-16	CsA+MTX+ATG	Pulmonary infection, acute GVHD II	Survival	–
4	CR	HLA5/10 related donor	Brother	TBI/Cy/VP16	CsA+MTX+ATG	Recurrence, multiple organ failure	Died	Recurrence, multiple organ failure
5	CR	HLA5/10 related donor	Mother	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD I	Survival	–
6	PR	HLA5/10 related donor	Mother	Bu/Cy/VP-16	CsA+MTX+ATG	Pulmonary infection, gastrointestinal bleeding	Died	Pulmonary infection, gastrointestinal bleeding
7	CR	HLA5/10 related donor	Sister	Bu/Cy/VP-16	CsA+MTX+ATG	Pulmonary infection	Survival	–
8	CR	HLA5/10 related donor	Brother	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD I, gastrointestinal bleeding	Survival	–
9	PR	HLA5/10 related donor	Brother	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD I	Survival	–
10	CR	HLA5/10 related donor	Father	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD II, pulmonary infection	Survival	–
11	CR	HLA5/10 related donor	Father	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD III, hemorrhagic cystitis	Survival	–
12	CR	HLA5/10 related donor	Father	TBI/Cy/VP-16	CsA+MTX+ATG	–	Survival	–
13	PR	HLA5/10 related donor	Father	TBI/Cy/VP-16	CsA+MTX+ATG	Acute GVHD I, pulmonary infection	Survival	–

allo-HSCT allogeneic hematopoietic stem cell transplantation, CR complete response, PR partial response, TBI total body irradiation, Cy cyclophosphamide, VP-16 etoposide, Bu busulfan, CsA cyclosporine A, MTX methotrexate, ATG anti-thymocyte globulin, GVHD graft versus host disease

ISSN: 1756-8722